Setting the Stage: The Rise of BCMA Bispecific Antibodies in Myeloma
| Setting the Stage: The Rise of BCMA Bispecific Antibodies in Myeloma This Around the Practice discussion series, BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: Real-World Integration and Patient-Centered Management, brings together leading experts Sundar Jagannath, MBBS, Icahn School of Medicine at Mount Sinai Hospital; Ajay Nooka, MD, MPH, FACP and Nisha Joseph, MD (Winship Cancer Institute of Emory University); Mohan Krishnamachary, MD (Suburban Hematology Oncology Associates); and Donna Catamero, MSN, ANP-BC, OCN, CBCN (Icahn School of Medicine at Mount Sinai Hospital), for a focused conversation recorded at ASH 2025. |
|
|
Featured Video |
 |
| Setting the Stage: The Rise of BCMA Bispecific Antibodies in Myeloma Experts discuss the rapid advancements in BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma, highlighting improved response rates and treatment integration. |
|